Development of the Gene Therapeutic Treatment to Mouse Senile Amyloidosis

点击翻译按钮获取中文摘要

Since, the effective treatment to amyloidosis is only the transplantation of the liver, we have done the basic studies for developing the gene therapeutic approach to amyloidosis. We used newly made congenic mice, R1.P1-Apoa2^c which are model mice of severe senile amyloidosis.1.Genetic analysis of mouse senile amyloidosis : In the congenic mice, R1.P1-Apoa2^<b/c> which are heterozygous for wild type B and amyloidogenic type C apoA-II,amyloid deposition was significantly slight. This finding suggested the possible availability of gene therapeutic approach. 2.Primary culture of the hepatic cell of the amyloidogenic mouse strain : Hepatic cells were isolated and cultured from R1.P1-Apoa2^c mice. 3.Evaluation system for the effectiveness of the gene therapy : Since the onset of amyloid deposition is usually after 8-12 month of age, we tried to develop a new system for evaluation the effect of gene therapy in relatively short period. Intravenous injection of amyloid fibrils AApoAII in R1.P1-Apoa2^c induced amyloid deposition at one month after injection. In R1.P1-Apoa2^<b/c>, amyloid deposition was significantly inhibited. 4.Adeno-virus with wild type apoA-II cDNA : Cosmid cassette (pAdexCAwt) which has human type 5 adenovirus (Ad5) and strong promoter unit, CAG (cytomegarovirus enhancer, chicken-actin promoter rabbit-globin polyA) was kindly provided by Dr.I.Saito in Tokyo University. Wild type apoA-II cDNA (Apoa2^c) was subcloned into Swal site of the cosmid and co-transformed with parental adeno virus DNA-TCP into the 293 cell. Several adeno viruses with wild type apoA-II cDNA produced by homologous recombination was selected.